RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy

Qifang Long, Weipei Zhu, Liangsheng Guo, Li Pu Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaCorrespondence: Weipei Zhu Email weipeizhu@163.comBackground: To establish a novel delivery system of RGD-conjugat...

Full description

Bibliographic Details
Main Authors: Long Q, Zhu W, Guo L, Pu L
Format: Article
Language:English
Published: Dove Medical Press 2020-12-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/rgd-conjugated-resveratrol-hsa-nanoparticles-as-a-novel-delivery-syste-peer-reviewed-article-DDDT
_version_ 1818612218330087424
author Long Q
Zhu W
Guo L
Pu L
author_facet Long Q
Zhu W
Guo L
Pu L
author_sort Long Q
collection DOAJ
description Qifang Long, Weipei Zhu, Liangsheng Guo, Li Pu Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaCorrespondence: Weipei Zhu Email weipeizhu@163.comBackground: To establish a novel delivery system of RGD-conjugated resveratrol human serum albumin (HAS) nanoparticles in ovarian cancer therapy.Methods: The nanoparticles system was characterized for physicochemical properties, the stability in the serum and in vitro release. The comparison between RVT injection, HSA-RVT NPs and RGD-HSA-RVT NPs regarding tissue distributions and pharmacokinetics was also carried out using mice as the animal models.Results: The results showed that RGD-HSA-RVT NPs were characterized of small particle size about 128.2 nm and negative zeta potential about − 21.42 mV, and drug controlled to release slowly on a biphasic pattern. Compared with control groups, RGD-HSA-RVT NPs showed the higher cellular uptake and cell inhibition rates. In vivo data showed that RGD-HSA-RVT NPs have good tumor enrichment characteristics and a significant difference in tumor inhibition, compared with the control group.Conclusion: RGD-conjugated resveratrol HSA nanoparticles are an ideal drug delivery system, which can play a role in the treatment of ovarian cancer.Keywords: resveratrol, HAS, nanoparticle, cellular uptake, cell viability, tissue distributions, pharmacokinetics
first_indexed 2024-12-16T15:42:44Z
format Article
id doaj.art-cc4cc4a0b17042c18cb505611b6e1481
institution Directory Open Access Journal
issn 1177-8881
language English
last_indexed 2024-12-16T15:42:44Z
publishDate 2020-12-01
publisher Dove Medical Press
record_format Article
series Drug Design, Development and Therapy
spelling doaj.art-cc4cc4a0b17042c18cb505611b6e14812022-12-21T22:25:56ZengDove Medical PressDrug Design, Development and Therapy1177-88812020-12-01Volume 145747575660754RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer TherapyLong QZhu WGuo LPu LQifang Long, Weipei Zhu, Liangsheng Guo, Li Pu Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaCorrespondence: Weipei Zhu Email weipeizhu@163.comBackground: To establish a novel delivery system of RGD-conjugated resveratrol human serum albumin (HAS) nanoparticles in ovarian cancer therapy.Methods: The nanoparticles system was characterized for physicochemical properties, the stability in the serum and in vitro release. The comparison between RVT injection, HSA-RVT NPs and RGD-HSA-RVT NPs regarding tissue distributions and pharmacokinetics was also carried out using mice as the animal models.Results: The results showed that RGD-HSA-RVT NPs were characterized of small particle size about 128.2 nm and negative zeta potential about − 21.42 mV, and drug controlled to release slowly on a biphasic pattern. Compared with control groups, RGD-HSA-RVT NPs showed the higher cellular uptake and cell inhibition rates. In vivo data showed that RGD-HSA-RVT NPs have good tumor enrichment characteristics and a significant difference in tumor inhibition, compared with the control group.Conclusion: RGD-conjugated resveratrol HSA nanoparticles are an ideal drug delivery system, which can play a role in the treatment of ovarian cancer.Keywords: resveratrol, HAS, nanoparticle, cellular uptake, cell viability, tissue distributions, pharmacokineticshttps://www.dovepress.com/rgd-conjugated-resveratrol-hsa-nanoparticles-as-a-novel-delivery-syste-peer-reviewed-article-DDDTresveratrolhasnanoparticlecellular uptakecell viabilitytissue distributionspharmacokinetics
spellingShingle Long Q
Zhu W
Guo L
Pu L
RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy
Drug Design, Development and Therapy
resveratrol
has
nanoparticle
cellular uptake
cell viability
tissue distributions
pharmacokinetics
title RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy
title_full RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy
title_fullStr RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy
title_full_unstemmed RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy
title_short RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy
title_sort rgd conjugated resveratrol hsa nanoparticles as a novel delivery system in ovarian cancer therapy
topic resveratrol
has
nanoparticle
cellular uptake
cell viability
tissue distributions
pharmacokinetics
url https://www.dovepress.com/rgd-conjugated-resveratrol-hsa-nanoparticles-as-a-novel-delivery-syste-peer-reviewed-article-DDDT
work_keys_str_mv AT longq rgdconjugatedresveratrolhsananoparticlesasanoveldeliverysysteminovariancancertherapy
AT zhuw rgdconjugatedresveratrolhsananoparticlesasanoveldeliverysysteminovariancancertherapy
AT guol rgdconjugatedresveratrolhsananoparticlesasanoveldeliverysysteminovariancancertherapy
AT pul rgdconjugatedresveratrolhsananoparticlesasanoveldeliverysysteminovariancancertherapy